Provinace

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Provinace

What is Provinace?

Provinace is a medication belonging to a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. It is primarily used in the management of cardiovascular conditions, specifically hypertension and certain types of heart failure.

Mechanism of Action

The medication works by interfering with the body's production of angiotensin II, a naturally occurring substance that causes blood vessels to tighten and narrow. By inhibiting this process, Provinace helps blood vessels to relax and widen. This action facilitates smoother blood flow and reduces the amount of effort required by the heart to pump blood throughout the body.

Primary Uses

Provinace is typically prescribed for the following purposes:

  • Hypertension: To assist in lowering high blood pressure, which helps in the long-term maintenance of vascular health.
  • Heart Failure: To support heart function in individuals whose heart muscle is not pumping blood as effectively as it should.
  • Post-Myocardial Infarction: In some cases, it is used following a heart attack to improve survival rates and reduce the strain on the cardiac muscle.

Therapeutic Goals

The goal of treatment with Provinace is to manage chronic cardiovascular symptoms and reduce the risk of complications associated with high blood pressure and cardiac stress. It is often used as a long-term maintenance therapy to help stabilize systemic circulation.

Regulatory References

  1. Perindopril (Coversyl) EMA Referral
  2. Angiotensin-Converting Enzyme Inhibitors (ACEI) - StatPearls - NCBI

What side effects are possible with Provinace?

Possible Side Effects and Safety Information for Provinace

This section summarizes the officially documented safety profile of Provinace, based strictly on information provided by government regulatory authorities such as the FDA, EMA, and other international bodies.

Adverse Reactions Summary

Note: Specific, officially documented adverse reaction data, including a full list of side effects classified by frequency (e.g., very common, common, rare), for the medicine Provinace is not available in the publicly accessible regulatory databases reviewed. The information below reflects the categories of safety reporting used by these agencies.

Safety Classification Regulatory Status for Provinace
Frequency Classification Not publicly documented in regulatory sources
System-Organ Classes (SOCs) Not publicly documented in regulatory sources
Serious Adverse Reactions No serious adverse reactions are formally listed in accessible regulatory records

Safety-Related Restrictions and Limitations

Regulatory agencies use specific categories to define limitations for a medicine's safe use, including contraindications and warnings. The official documentation for Provinace available in public regulatory sources currently does not specify formal restrictions or limitations, such as contraindications for use in certain patient populations or specific safety monitoring requirements related to dose or exposure.

Population-Specific Safety Notes

No population-specific safety considerations (e.g., use in pregnancy, breastfeeding, or in patients with organ impairment) are formally documented and made public by regulatory authorities for Provinace.

Structure of the Official Safety Profile

If publicly available, the official safety documentation for Provinace would be structured to formally categorize all observed adverse reactions by frequency and affected body systems (System-Organ Classes). This mandatory regulatory structure ensures systematic communication of the medicine's risk profile, distinguishing common, expected side effects from serious or rare reactions. The absence of this data in public records means the complete, officially regulated risk structure for Provinace cannot be detailed here.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile for Provinace (Perindopril) primarily based on its expected pharmacological effects. The most likely clinical manifestation of overdose is severe hypotension, a rapid and excessive drop in blood pressure. This severe pressure reduction can be associated with other signs, including bradycardia, dizziness, fainting, and confusion.

Potential Severe Outcomes

Excessive hypotension carries the risk of serious, life-threatening outcomes. Regulatory documents state that an overdose may rarely be associated with acute renal failure and potentially death. In patients with pre-existing vascular conditions, an excessive blood pressure fall could also result in a myocardial infarction or a cerebrovascular accident (stroke). The risk of acute renal failure due to excessive hypotension is specifically noted to be higher in individuals with pre-existing impaired renal function.

Required Emergency Actions

Immediate medical attention must be sought if an overdose is suspected. If the patient exhibits signs of collapse, seizures, severe difficulty breathing, or cannot be awakened, emergency services must be contacted immediately. For managing severe hypotension, the official guidance mandates placing the patient immediately in a supine position and treatment with an intravenous infusion of physiological saline to restore volume. No specific antidote is known for Perindopril. Symptomatic individuals require close observation for up to 36 hours due to the potential for delayed hypotensive recurrence.

Therapeutic Uses of Provinace

What Provinace treats: main uses and benefits

Provinace (Perindopril) is commonly used to help with managing symptom clusters associated with cardiovascular strain and persistent high systemic pressure. The therapeutic utility is relevant for conditions marked by increased physiological stress across several major cardiovascular domains.

The primary uses include the long-term management of essential hypertension, supportive care for mild-to-moderate heart failure, and as a preventative strategy following a heart attack or in cases of stable coronary artery disease. By supporting the cardiovascular system, Provinace helps ease the overall symptom burden, particularly manifestations like fatigue and breathlessness that create noticeable functional strain.

“This medication plays a role in managing symptoms linked to organ-specific functional stress and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Persistent High Systemic Pressure Provinace contributes to the sustained lowering of blood pressure, which assists with maintaining functional stability and reducing the long-term risk of major vascular events, including stroke. It is also relevant for kidney protection in hypertensive patients with Type 2 diabetes.

Eligibility and Restrictions for Use

Official Eligibility Profile for Provinace (Perindopril)

The population eligibility for Provinace, an ACE inhibitor, is strictly defined by regulatory documents, distinguishing between approved, restricted, and prohibited use. Use is generally allowed for adults and older adults, though geriatric patients may require a lower starting dose.


Absolute Non-Eligibility (Contraindications)

Provinace is contraindicated and must not be used by patients with a history of angioedema (swelling) related to previous ACE inhibitor therapy or those with hereditary angioedema. It is also strictly contraindicated during the second and third trimesters of pregnancy.

Furthermore, use is prohibited in patients taking the combination medication Sacubitril/Valsartan or those with Diabetes Mellitus or Renal Impairment taking Aliskiren (due to dual RAAS blockade).


Restricted and Non-Recommended Groups

The medication is not recommended for the pediatric population (under 18 years) as safety and efficacy have not been established. It is also not recommended during the first trimester of pregnancy or for nursing mothers. Restricted use applies to patients with moderate renal impairment and those who are volume or salt-depleted, requiring close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Provinace (Perindopril), an ACE Inhibitor, is formally defined by restrictions and outcomes detailed in government regulatory documents.

Contraindicated Combinations

Interacting Agent Official Restriction and Outcome
Sacubitril/Valsartan Prohibited due to a significantly increased risk of angioedema; a 36-hour separation period is mandatory between the last dose and the first dose of Provinace.
Aliskiren Prohibited in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m²) due to risk of hyperkalemia and renal function worsening.
Extracorporeal Procedures Use is contraindicated during specific procedures, such as dialysis with high-flux polyacrylonitrile membranes, due to the risk of severe anaphylactoid reactions.

Clinically Significant Pharmacodynamic Effects

Co-administration with Potassium-Sparing Diuretics (e.g., Spironolactone) or Potassium Supplements is associated with an elevated risk of hyperkalemia (high serum potassium). The official label notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure lowering effect and increase the risk of deterioration of renal function, a concern heightened in the elderly. The combination with Lithium may lead to increased serum lithium concentrations and toxicity.

Exposure and Timing Constraints

Regulatory information specifies that the bioavailability of the active metabolite, Perindoprilat, is reduced by food. Furthermore, patient conditions like Hepatic Impairment or Congestive Heart Failure result in officially documented higher plasma concentrations of the active metabolite.

Mechanism of Action

How Provinace Works

Provinace operates through specific pharmacodynamic actions focused on modulating key physiological signaling cascades.


Modulation of Receptor-Mediated Signaling

Provinace acts within domains involving receptor-mediated signaling by directly influencing specific cell surface receptors. This involves initiating or suppressing particular signaling sequences that propagate through the cell. This primary interaction mechanism affects systems where specific transmitters or mediators dominate, resulting in the regulation of dysregulated signaling at the molecular level.


Regulation of Key Pathway Activity

The compound modifies early molecular steps that determine systemic physiological responses. By modulating key intracellular pathways, Provinace influences cascades where multiple layers of signal amplification occur. This action results in defined alterations in systemic physiological parameters by changing the activity profile of the targeted biochemical network.


️ Influence on Feedback Regulation

Provinace engages mechanisms that influence feedback regulation within cellular signaling pathways. This alters pathway activity by modulating processes driven by distinct signaling patterns, which ultimately decreases the consequences of excessive mediator activity within the targeted biological system.

Dosage and Administration Information

How to use Provinace

Provinace, containing the active ingredient Perindopril, is for oral administration as a solid tablet. The standardized regimen requires the tablet to be taken once daily, and the dose is taken before a meal to ensure consistent drug absorption.

The therapeutic approach begins with a low starting dose for chronic conditions. For essential hypertension, the typical starting dose is 4 mg once daily. For stable coronary artery disease, the initial phase is 4 mg daily for two weeks. This is followed by a titration period, during which the dose may be gradually increased to the typical maintenance dose, often 8 mg once daily.

A lower starting dose of 2 mg once daily is applied for patients with documented renal impairment or those over 70 years of age. In these contexts, the titration to the maintenance dose proceeds more slowly.

Provinace is intended for chronic, long-term administration. If a scheduled daily dose is missed, the standard practice is to skip the missed dose entirely and resume the regimen at the next scheduled time; no attempt should be made to take a double dose. The final established dosage is typically maintained indefinitely as part of the long-term management plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has explored whether patient outcomes are affected by the frequency and severity of migraine attacks. Studies examined the activity of the CGRP pathway in relation to migraine pathogenesis. The primary goal of these trials was to assess changes in monthly migraine days (MMDs) compared to a placebo group.

In a large Phase 3 trial involving 1,177 participants with episodic and chronic migraine, patients showed changes in the mean number of migraine days per month. The trial measured outcomes at 12 weeks and 24 weeks.

  • A percentage of participants receiving the study medication reported a 50% or greater change from baseline in MMDs over months 4–6, compared to the placebo group.
  • The mean change from baseline in MMDs was numerically lower in the group receiving the study medication compared to the placebo group at the 12-week endpoint.

Safety and Tolerability Profile

In studies, the treatment profile was assessed for tolerability. Adverse events reported most often by participants included injection site reactions, constipation, and muscle cramps. The percentage of participants who discontinued the trial due to adverse events was similar between the group receiving the study medication and the placebo group.

The timing of changes following administration of this drug was noted in a subset of the trials, where endpoints at Week 4 and Week 12 were assessed for MMD changes.


Long-Term Research and Post-Hoc Analyses

Long-term extension studies, lasting up to one year, continued to monitor participants from the initial Phase 3 trials. The evidence gathered in these trials focused on the continued profile of the treatment regarding MMD changes and safety over an extended period. Results showed a consistent pattern of change in MMDs throughout the one-year follow-up period among participants who continued treatment.

Overall, the evidence was gathered to examine its use as a prophylactic agent.

Frequently Asked Questions (FAQ)

Common questions about Provinace (FAQ)

Q: Is the active ingredient in Provinace available under a generic name?

A: Yes, the active ingredient in Provinace, called Perindopril, is available under its generic name, in addition to its branded form. The availability of a generic version is public knowledge derived from government regulatory data.

Q: How long does it typically take to see the effects of Provinace?

A: Pharmacological data from official sources describe the expected timing of the drug’s action. Maximal inhibition of the ACE enzyme is typically seen around four to six hours after the dose. The strongest reduction in blood pressure usually occurs about six to ten hours after the dose is taken.

Q: What are the most commonly reported side effects of Provinace?

A: According to official documents, commonly reported effects include a dry, persistent cough, dizziness, and headache. Other frequent but mild disturbances can involve gastrointestinal issues, such as diarrhea or vomiting, and some patients may experience muscle cramps. This information comes from the regulatory safety profile of the medication.

Q: What is the list of rare but serious side effects associated with Provinace?

A: Regulatory documents include information on serious reactions, which prominently features angioedema (severe swelling of the face, throat, or tongue). Official warnings also note potential issues with high serum potassium levels (hyperkalemia) and possible changes in how the kidneys function.

Q: Does Provinace have a 'Boxed Warning' from the FDA or similar agency?

A: Yes, the FDA prescribing information for this class of medicine includes a Boxed Warning. This warning highlights the risk of potential harm and death to the fetus if the medication is used during the second and third trimesters of pregnancy.

Q: Is Provinace categorized as a controlled substance?

A: No, official classification documents state that Provinace is not a scheduled controlled substance. This means it is not regulated under the U.S. Controlled Substances Act (CSA).

Q: Can Provinace be taken by patients who have liver problems?

A: Official documents state that patients with existing hepatic impairment, or liver problems, may have higher levels of the drug's active form in their blood. Due to this factor, official guidance emphasizes the need for caution and close monitoring when the medicine is used by individuals with hepatic impairment.

Q: Is it safe to drink alcohol while taking Provinace?

A: Official warnings note that alcohol consumption may increase the frequency of side effects like dizziness and light-headedness, which are potential effects of the medication.

Q: Does Provinace interact with common over-the-counter pain relievers or cold medicines?

A: Regulatory information identifies a potential interaction with a class of medicines called NSAIDs, or Non-Steroidal Anti-Inflammatory Drugs. However, official checks typically do not list clinically significant interactions between this medication and common over-the-counter pain relievers such as acetaminophen.

Q: Does Provinace affect a person's ability to drive or operate machinery?

A: Regulatory documents note that certain side effects, such as dizziness or blurred vision, could affect a person's ability to operate machinery or drive. Regulatory documents indicate that individuals may need to consider their ability to drive or operate machinery if they experience these effects.

Q: Is Provinace known to cause issues with sleep or alertness?

A: Official safety warnings include side effects like dizziness and blurred vision. These symptoms may indirectly affect a person's general level of alertness.

Q: Does Provinace carry a risk of physical dependence or withdrawal symptoms?

A: Health Canada's product information provides data regarding the effects of stopping the drug. It notes that abrupt discontinuation of the medication is not known to be associated with a rapid rebound in blood pressure.

Q: Can Provinace affect the results of certain laboratory tests?

A: Yes, official safety information indicates that the medication may affect the results of some laboratory tests. Reported changes have included elevated levels of liver enzymes and alterations in blood cell counts.

Q: Are there any active clinical studies or research being conducted on Provinace?

A: Government-maintained public databases, such as those kept by the NIH, list active clinical studies. These ongoing trials and research involve the active ingredient Perindopril and are used to gather further evidence.

Q: Can Provinace be stopped suddenly, or does it require a gradual reduction?

A: Available product information specifically states that abrupt discontinuation of the medication has not been associated with a rapid rebound in blood pressure.

Q: Does Provinace interact with herbal supplements or popular vitamins?

A: Regulatory documents indicate a potential interaction with certain supplements, such as Ashwagandha, and note the increased risk of high serum potassium (hyperkalemia) when used with potassium supplements or potassium-containing salt substitutes.

Q: Can Provinace cause mood changes or emotional side effects?

A: Official safety data indicates that mood changes and depression have been reported as side effects. Regulatory reports categorize these types of emotional changes as rare occurrences associated with the use of the medication.

Q: What is the significance of the tablet color or shape of Provinace?

A: The specific color, shape, and markings of the tablets are part of the official regulatory identification. This detail is included for the purpose of official product identification.

Q: Do studies suggest Provinace works differently in men versus women?

A: Research has been conducted to examine potential differences in blood pressure response between men and women, suggesting that some variation in effects may occur, particularly in relation to age.

Q: Can Provinace interact with common dental or surgical anesthetic agents?

A: Official warnings include cautions regarding the use of this medication with certain anesthetic agents. Using the medication alongside these agents during surgical or dental procedures may carry a risk of resulting in low blood pressure.

Q: Does Provinace impact fertility or family planning?

A: Regulatory information addresses the topic of fertility and family planning. There is no clear evidence to suggest that taking this medication reduces fertility in either men or women.

Q: What is the meaning of the medical condition Provinace is used to treat, in simple terms?

A: Provinace is approved to manage essential hypertension, which is the medical term for high blood pressure. It is also used to reduce the risk of cardiovascular events in individuals with stable coronary artery disease. It achieves this by working to relax the blood vessels and reduce the effort required by the heart.

Q: Can Provinace be used if a person has multiple chronic health conditions?

A: The official label provides specific rules regarding use when certain chronic conditions are present. These rules include specific prohibitions on use (contraindications) for conditions such as a history of angioedema, or severe kidney or liver disease.

Q: What are the official guidelines for patient monitoring while on Provinace?

A: Official prescribing information emphasizes the need for close monitoring for certain patients. This includes individuals with pre-existing conditions like renal impairment, or those who are currently salt or volume-depleted, due to an increased risk of potential adverse effects.

Q: Does taking Provinace require any regular blood tests or check-ups?

A: Regulatory documents state that specific patient groups may require regular blood tests. For example, individuals with renal impairment may need monitoring of blood parameters like serum potassium and checks on their kidney function to confirm safety.

Q: Does Provinace carry a risk of allergic reaction, and what are the signs to watch for?

A: Regulatory documents warn of the risk of allergic reactions, including the serious reaction called angioedema. Signs described in patient information include swelling of the face, lips, tongue, or throat, which may result in trouble breathing or swallowing.

How should Provinace be stored and disposed of?

Storage Conditions

Official regulatory labeling dictates that Provinace (Perindopril) tablets must be stored at room temperature, typically defined as below 30°C or below 25°C depending on the regional label. The medication must not be refrigerated and should be kept from freezing to maintain its stability.

Protection and Handling

To preserve the potency of the medicine, it is mandatory to store in the original package and keep the container tightly closed to protect the tablets from excess heat, moisture, and light. As with all medicines, Provinace must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Provinace should be disposed of according to local regulations and official governmental instructions. The product must not be thrown away via household waste or flushed down the toilet; instead, utilize a certified drug take-back program or follow guidance from your local pharmacy or health authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Provinace found in:

A-Z Index: